Search results for "Heart Valve Prosthesis"

showing 10 items of 66 documents

Incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio.

2008

Objective Subtherapeutic international normalized ratios are frequently encountered in clinical practice, and patients with mechanical heart valves with inadequate anticoagulation may be exposed to an increased risk of thromboembolic events. There are no data on thromboembolic event risk for these patients. Methods We assessed the current practice patterns in the management of patients with mechanical heart valves with subtherapeutic international normalized ratios and assessed the risk of thromboembolic complications in this setting. The charts of patients with mechanical heart valves followed up in two anticoagulation clinics were reviewed. Patients with a history of stable, therapeutic a…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classLow molecular weight heparinProsthesis DesignRisk AssessmentSettore MED/15 - Malattie Del SangueCohort StudiesYoung AdultThromboembolismAntithromboticmedicineHumansInternational Normalized RatioINR anticoagulant mechanical heart valvesAgedRetrospective Studiesbusiness.industryIncidenceIncidence (epidemiology)Retrospective cohort studyMiddle AgedVitamin K antagonistConfidence intervalSurgeryHeart Valve ProsthesisFemaleSurgeryRisk assessmentbusinessCardiology and Cardiovascular MedicineCohort study
researchProduct

Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: The use of fixed sub-therap…

2012

No data are available regarding the management of cancer patients requiring interruption of long-term vitamin-K antagonist (VKA) therapy. For this purpose, we tested the efficacy and safety of fixed doses of low-molecular weight heparin (LMWH) in substitution of VKA because of invasive procedures or chemotherapy-induced thrombocytopenia. In cancer patients on VKA, therapy was discontinued 5 ± 1 days before surgery or chemotherapy. Heparin was given at prophylactic dosage in patients at low risk and at fixed subtherapeutic doses (3,800 or 4,000 UI anti-FXa, b.i.d.) in those at high-risk for thrombosis. LMWH was reinitiated 12 hr after surgery and VKA the day after. In patients receiving chem…

AdultMaleRiskmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentLow molecular weight heparinAntineoplastic AgentsHemorrhagelow-molecular weight heparin (LMWH); long-term vitamin-K antagonist (VKA) therapy; cancer patientsSettore MED/15 - Malattie Del SanguePostoperative ComplicationsNeoplasmsThromboembolismAtrial FibrillationHumansThrombophiliaMedicinecancer thrombocytopenia low molecular weight heparinProspective StudiesProspective cohort studyAgedAged 80 and overChemotherapybusiness.industryIncidenceWarfarinAnticoagulantsCancerHematologyHeparinHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombocytopeniaThrombosisSurgeryClinical trialHeart Valve ProsthesisAnesthesialow-molecular weight heparin (LMWH)FemaleWarfarinlong-term vitamin-K antagonist (VKA) therapycancer patientsbusinessmedicine.drugAmerican Journal of Hematology
researchProduct

Clinical relevance of vegetation localization by transoesophageal echocardiography in infective endocarditis

1992

Infective endocarditis is associated with significant morbidity and mortality, with valvular destruction and congestive heart failure being more common in patients with echocardiographically discernible vegetations. The transoesophageal approach affords consistently high quality images with excellent structural resolution. Two-hundred and eighty-one patients with clinically suspected infective endocarditis were studied, to evaluate the prognostic value of ascertaining the site of vegetations. Among them were 118 patients with vegetations attached to the aortic or mitral valve. These patients were followed for a mean period of 14 months. Mitral valve vegetations were associated with a signif…

AdultMalemedicine.medical_specialtyAortic Valve InsufficiencyPostoperative ComplicationsSepsisStreptococcal InfectionsMitral valveInternal medicinemedicineHumansEndocarditisProspective StudiesHeart valveProspective cohort studyAbscessbusiness.industryMitral Valve InsufficiencyEndocarditis BacterialIntracranial Embolism and ThrombosisMiddle AgedStaphylococcal InfectionsPrognosismedicine.diseaseAbscessSurgerymedicine.anatomical_structureEmbolismEchocardiographyAortic ValveHeart Valve ProsthesisHeart failureInfective endocarditisCardiologyMitral ValveFemaleCardiology and Cardiovascular MedicinebusinessEuropean Heart Journal
researchProduct

Detection of spontaneous echocardiographic contrast within the left atrium by transesophageal echocardiography: spontaneous echocardiographic contrast

1986

Transesophageal echocardiography was performed in 314 patients over a period of 24 months using a 3.5 MHz phased-array system fitted to the distal end of a conventional 12 mm endoscope. In 12 patients (2.6%) transesophageal echocardiography could not be performed because of adverse reaction to the gastroscopic procedure. Side effects were a transient A-V block in one patient and asthmatic attack in another. Mitral valve lesions were found in 99 of 314 patients. In 9 of these 99 patients (11%), including 1 patient with mitral valve stenosis and sinus rhythm, 2 with atrial fibrillation, 3 with disc, and 3 with porcine mitral prosthesis, spontaneous echocardiographic contrast was found within …

AdultMalemedicine.medical_specialtyEndoscopeEsophagusPostoperative ComplicationsMitral valve stenosisInternal medicineMitral valveHumansMitral Valve StenosisMedicineSinus rhythmHeart AtriaEsophagusbusiness.industryMitral Valve InsufficiencyThrombosisAtrial fibrillationGeneral MedicineIntracranial Embolism and ThrombosisMiddle Agedmedicine.diseasePeripheralmedicine.anatomical_structureEmbolismEchocardiographyHeart Valve Prosthesiscardiovascular systemCardiologyFemaleRadiologyCardiology and Cardiovascular MedicinebusinessClinical Cardiology
researchProduct

Coronary embolism in a young patient with nonbacterial thrombotic endocarditis related to antiphospholipid syndrome

2020

myocardial infarction

AdultMalemedicine.medical_specialtyMEDLINEMagnetic Resonance Imaging CineCoronary AngiographyNonbacterial thrombotic endocarditisAntiphospholipid syndromeInternal medicinemedicineHumansAngioplasty Balloon Coronarycoronary embolismHeart Valve Prosthesis Implantationbusiness.industryGeneral MedicineAntiphospholipid SyndromeCoronary embolismmedicine.diseaseAortic Valve DiseaseTreatment OutcomeCoronary OcclusionEndocarditis Non-InfectiveCardiologyST Elevation Myocardial InfarctionCardiology and Cardiovascular MedicinebusinessEchocardiography TransesophagealTomography Optical Coherence
researchProduct

Clopidogrel and aspirin in the prevention of thromboembolic complications after mechanical aortic valve replacement (CAPTA)

2003

Axel Schlitt*, Ralf S. von Bardeleben, Anne Ehrlich, Antje Eimermacher, Dirk Peetz, Manfred Dahm, Hans J. Rupprecht Department of Medicine II, Johannes Gutenberg-University Mainz, Langenbeckstr. 1, 55131 Mainz, Germany Coordination Center for Clinical Studies, Johannes Gutenberg-University Mainz, Mainz, Germany Clinic for Clinical Chemistry and Laboratory Medicine, Johannes Gutenberg-University Mainz, Mainz, Germany Department of Cardiothoracic and Vascular Surgery, Johannes Gutenberg-University Mainz, Mainz, Germany

AdultMalemedicine.medical_specialtyTiclopidineTreatment outcomeAdministration OralHemorrhagePilot ProjectsValvula aorticaProstaglandin-Endoperoxide SynthaseThromboembolismmedicineHumansOral anticoagulationAgedAspirinAspirinbusiness.industryHematologyMiddle AgedClopidogrelClopidogrelSurgeryTreatment OutcomeAortic ValveHeart Valve ProsthesisAortic valve surgeryPhenprocoumonDrug Therapy CombinationFemalebusinessVenous diseasemedicine.drugThrombosis Research
researchProduct

Monitoring prothrombin fragment 1+2 during initiation of oral anticoagulant therapy after intracoronary stenting

1992

Patients with intracoronary stent implantation are treated with aggressive anticoagulant and antiplatelet therapy consisting of high-dose heparin, phenprocoumon, acetylsalicylic acid, dipyridamole, and the infusion of dextran to prevent a subacute thrombotic occlusion of the stented segment. In an effort to optimize this treatment by reducing both imminent bleeding complications and subacute thrombotic occlusion, the concentrations of prothrombin fragment 1 + 2 (F 1 + 2) were determined after intracoronary Palmaz-Schatz stent implantation in 19 consecutive patients. The F 1 + 2 concentrations after stent implantation and before the initiation of oral anticoagulant therapy (OAT) were 0.35 nm…

AdultMalemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentUrologyAdministration OralPhenprocoumonmedicineHumansAngioplasty Balloon CoronaryAgedChemotherapyHeparinbusiness.industryPROTHROMBIN FRAGMENT 1.2AnticoagulantAnticoagulantsHematologyGeneral MedicineHeparinMiddle AgedThrombophlebitismedicine.diseaseThrombosisPeptide FragmentsDipyridamoleHeart Valve ProsthesisAnesthesiaPhenprocoumonFemaleProthrombinStentsPulmonary EmbolismComplicationbusinessmedicine.drugAnnals of Hematology
researchProduct

Regurgitant flow in apparently normal valve prostheses: improved detection and semiquantitative analysis by transesophageal two-dimensional color-cod…

1990

In 128 patients with apparently normally functioning prosthetic valves ( n = 136) in the aortic position ( n = 79) and the mitral position ( n = 57), the prevalence of transprosthetic regurgitant flow was studied by use of transthoracic and transesophageal two-dimensional color-coded Doppler echocardiography. With the transthoracic approach, regurgitant flow was detected in early systole or diastole for 28% of the mitral prostheses and for 29% of the aortic prostheses. With transesophageal color-coded Doppler echocardiography, regurgitant jets were visualized for 95% of the mitral prostheses and for 44% of the aortic prostheses. In 40% of the Bjork-Shiley prostheses and 88% of the St. Jude …

Aortic valveAdultMalemedicine.medical_specialtyAdolescentAortic Valve InsufficiencyDiastoleDoppler echocardiographyInternal medicineMitral valvemedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesSystoleTransthoracic approachAgedmedicine.diagnostic_testbusiness.industryMiddle Agedequipment and suppliesEchocardiography DopplerRegurgitant flowProsthesis Failuremedicine.anatomical_structureAortic ValveHeart Valve Prosthesiscardiovascular systemCardiologyMitral ValveFemaleCardiology and Cardiovascular MedicinebusinessSemi quantitativecirculatory and respiratory physiologyJournal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
researchProduct

Heart valve tissue engineering: how far is the bedside from the bench?

2015

Heart disease, including valve pathologies, is the leading cause of death worldwide. Despite the progress made thanks to improving transplantation techniques, a perfect valve substitute has not yet been developed: once a diseased valve is replaced with current technologies, the newly implanted valve still needs to be changed some time in the future. This situation is particularly dramatic in the case of children and young adults, because of the necessity of valve growth during the patient's life. Our review focuses on the current status of heart valve (HV) therapy and the challenges that must be solved in the development of new approaches based on tissue engineering. Scientists and physicia…

Aortic valveHeart diseaseSwine030204 cardiovascular system & hematology0302 clinical medicineHeart valve tissue engineeringHyaluronic AcidChildProsthetic valve0303 health sciencesMARROW-DERIVED CELLSTissue ScaffoldsFetal BloodHeart Valves3. Good healthmedicine.anatomical_structureHeart Valve ProsthesisCardiologyMolecular MedicineCollagenmedicine.medical_specialtyPULMONARY VALVEBONE-MARROWInduced Pluripotent Stem CellsVENTRICULAR OUTFLOW TRACTMESENCHYMAL STEM-CELLS03 medical and health sciencesTissue scaffoldsInternal medicineEXTRACELLULAR-MATRIXmedicineAnimalsHumansHeart valveIntensive care medicineENDOTHELIAL PROGENITOR CELLSMolecular Biology030304 developmental biologyBioprosthesisAORTIC-VALVEFibrinSheepTissue Engineeringbusiness.industryEndothelial Cellsmedicine.diseaseTransplantationPulmonary valveUMBILICAL-CORD BLOOD1182 Biochemistry cell and molecular biologybusinessHUMAN AMNIOTIC-FLUIDExpert Reviews in Molecular Medicine
researchProduct

A multicentre European registry to evaluate the Direct Flow Medical transcatheter aortic valve system for the treatment of patients with severe aorti…

2016

Aims Our aim was to assess the clinical outcomes of the Direct Flow Medical Transcatheter Aortic Valve System (DFM-TAVS), when used in routine clinical practice. Methods and results This is a prospective, open-label, multicentre, post-market registry of patients treated with DFM-TAVS according to approved commercial indications. Echocardiographic and angiographic data were evaluated by an independent core laboratory and adverse events were adjudicated and classified according to VARC-2 criteria by an independent clinical events committee. The primary endpoint was freedom from all-cause mortality at 30 days post procedure. Secondary endpoints included procedural, early safety and efficacy en…

Aortic valveMalemedicine.medical_specialtyCardiac Catheterizationmedicine.medical_treatmentAortic Valve InsufficiencyRegurgitation (circulation)030204 cardiovascular system & hematologyTranscatheter Aortic Valve Replacement03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineClinical endpointHumans030212 general & internal medicineHeart valveProspective StudiesRegistriesCardiac catheterizationAgedAged 80 and overHeart Valve Prosthesis Implantationbusiness.industryAortic Valve Stenosismedicine.disease3. Good healthClinical trialStenosismedicine.anatomical_structureTreatment OutcomeAortic valve stenosisAortic ValveHeart Valve ProsthesisCardiologyFemaleCardiology and Cardiovascular MedicinebusinessEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
researchProduct